Updates are available Correction dated 2024-12-24

Article History

Received: 10 June 2024

Accepted: 20 August 2024

First Online: 17 September 2024

Change Date: 26 December 2024

Change Type: Update

Change Details: The original online version of this article was revised to correct the Figures 3 and 4.

Change Date: 24 December 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40122-024-00692-5

Declarations

:

: Andrew M. Blumenfeld has served on advisory boards Allergan, Aeon, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Pfizer, Revance, Teva, Theranica, Tonix. AB has been a speaker for Allergan/AbbVie, Lilly, Lundbeck, Teva, Theranica. AB has consulted for Aeon, Allergan/AbbVie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Pfizer, Novartis, Teva, Theranica, Tonix. AB has received grand support from Aeon, Allergan/AbbVie, Amgen, Lundbeck, Revance. AB has been a contributing author for Aeon, Allergan/AbbVie, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, Theranica. AB has received stock options from Haven Health Inc. and Aeon. Andrew Blumenfeld is an Editorial Board member of <i>Pain and Therapy</i>. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Laszlo Mechtler has served on advisory boards for, consulted for, and/or been a speaker for, Amgen, Novartis, Allergan/AbbVie, Eli Lilly, Teva, Biohaven, Lundbeck, The institution of Dr. Mechtler has received research support from The Harry Dent Family Foundation, Inc., Amgen/ Novartis, Alder/ Lundbeck, AbbVie/ Allergan, Miles for Migraine, and American Migraine Foundation. Lisa Cook has served on advisory boards for, consulted for and/or been a speaker for AbbVie/Allergan, Impel, Biohaven and Teva. Christopher Rhyne has served on advisory boards for, consulted for, and/or been a speaker for AbbVie/Allergan, Amgen, Biohaven, Diamond Headache Clinic Research and Education Foundation, Lilly, Lundbeck, National Headache Foundation, Teva, and Theranica. Brian Jenkins has served on advisory boards for, consulted for, and/or been a speaker for Amgen, Novartis, Allergan/AbbVie, Eli Lilly, Teva, Biohaven, Lundbeck, Relivion. Brian Jenkins has received stock or an ownership interest from Prevacus and NeoCorTechs. Merle Diamond has served on advisory boards for, consulted for, served as an editor for, and/or been a speaker or contributing author for Allergan/AbbVie, Amgen, Assertio, Axsome Pharma, Eli Lilly, Impel NeuroPharma, Lundbeck, Promius Pharma, Supernus, Upsher-Smith, Teva. An immediate family member of Merle Diamond has received compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Supernus and Teva. Olivia Hughes is an employee of ICON plc. Aubrey Manack Adams and Brett Dabruzzo are employees of AbbVie and may hold AbbVie stock.

: The New England Independent Review Board reviewed the study protocol prior to study initiation and determined the study as exempt from review. Written informed consent from participants was not required for this study in accordance with the national legislation and the institutional requirements as only deidentified data were collected. The study was conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki.